Drug Hunter
Molecules of the Year Symposium
November 19, 2026
About
📍MassBio, Cambridge, MA
Join Drug Hunter for our inaugural Symposium — an invite-only, one-day scientific meeting celebrating the breakthrough molecules and discovery teams shaping the future of drug discovery.
Preliminary Agenda
8:00am – 4:00pm | Symposium
4:00pm – 6:00pm | Happy Hour Mixer
🍴 Breakfast, Lunch, and Happy Hour provided
Who is Attending
Senior leaders and executives in drug discovery across pharma and biotech
Any profits will be donated to the American Cancer Society.
Details
- Chair: Dean Brown, SVP and Head of Research at Jnana Therapeutics
- Keynote: Jan Smith, CSO at Revolution Medicines
- Molecules of the Year speakers from large pharma and biotech companies
- 2025 Molecules of the Year Nominees
- 2024 Molecules of the Year Nominees
- 2023 Molecules of the Year Nominees
- 2022 Molecules of the Year Nominees
- 2021 Molecules of the Year Nominees
- Session to identify 2026 Molecules of the Year nominees
- Panel discussion on industry trends
How to Attend
Due to high interest, the symposium is invite-only. If you are interested in attending this exclusive event, please apply to attend.
| Time | Session |
| 8:00-8:30 AM |
Registration, Breakfast & Networking |
| 8:30–8:45 AM | Welcome & Drug Hunter Overview |
| 8:45-8:50 AM | Opening Remarks |
| Molecules of the Year | |
| 8:50-9:25 AM | Invention of Lipfendra — Abbas Walji, Merck |
| 9:25-10:05 AM | The Discovery of PAXLOVID — Dafydd Owen, Pfizer |
| 10:05-10:20 AM | Coffee Break |
| 10:20-10:55 AM | Harness Cutting-Edge Tools in Drug Discovery to Identify Potent and Selective IRAK4 Degraders — Yi Zhang, Kymera Therapeutics |
| 10:55-11:40 AM | Aficamten (CK-274): A Journey from Early Discovery to FDA Approval — Grace Chuang, Cytokinetics |
| 11:40 - 11:50 AM | Molecule of the Year Nomination |
| 11:50 AM–12:40 PM | Lunch & Networking |
| Keynote Presentation | |
| 12:40–1:30 PM | Discovery of Daraxonrasib, a RAS(ON) Multi-Selective Tri-Complex Inhibitor — Jan Smith, Revolution Medicines |
| 1:30-1:45 PM | Coffee Break |
| Emerging Modalities in Drug Discovery | |
| 1:45-2:20 PM | DAC Platform — Christopher Phelps, Nurix |
| 2:20-3:00 PM | Covalent Allosteric Target Modulation and the Discovery of VVD-037, a First-in-Class KEAP1 Activator — David Weinstein, Vividion |
| 3:00-3:50 PM | Panel Discussion |
| Dean Brown; Wendy Young; Dan Erlanson | |
| 3:50–4:00 PM | Closing Remarks |
| 4:00-6:00 PM | Networking Mixer |
Invite-Only Admission
Speakers
Dean Brown
Senior Vice President and Head of Research, Jnana Therapeutics
![]()
Jan Smith
CSO, Revolution Medicines
![]()
Keynote Speaker
Dafydd Owen
Senior Scientific Director, Pfizer
![]()
Speaker
Grace Chuang
Senior Research Fellow, Cytokinetics
![]()
Speaker
Christopher Phelps
SVP and Head of Early Drug Discovery, Nurix
![]()
Speaker
David Weinstein
SVP, Head of Medicinal Chemistry, Vividion Therapeutics
![]()
Speaker
Yi Zhang
Senior Director of Medicinal Chemistry, Kymera
![]()
Abbas Walji
Senior Director, Discovery Chemistry, Merck
![]()
Speaker
Wendy Young
Scientific Advisor
Panelist
Daniel Erlanson
Chief Innovation Officer, Frontier Medicines
![]()
Panelist